Market Place
Sourcing Support
Aardvark Therapeutics Secures $94M IPO For Obesity Drugs
13 Feb 2025 //
BIOSPACE
Aardvark Therapeutics Announces Pricing of Initial Public Offering
12 Feb 2025 //
GLOBENEWSWIRE
Ascentage Pharma’s US Shares Climb After $126 M IPO
25 Jan 2025 //
FIERCE BIOTECH
Aardvark Adds Roy Baynes & Susan Graf To Its Board Of Directors
09 Jan 2025 //
BUSINESSWIRE
Aardvark Therapeutics Expands Management Team with Two Key Hires
10 Sep 2024 //
PR NEWSWIRE
Aardvark Therapeutics Announces $85 Million Oversubscribed Series C Financing
09 May 2024 //
PR NEWSWIRE
Aardvark nabs $85M to target hunger, not appetite, as it eyes 2026 NDA filing
09 May 2024 //
ENDPTS
GRI Bio Enters into Asset Purchase Agreement with Aardvark Therapeutics
23 Aug 2023 //
GLOBENEWSWIRE
Aardvark Announces Receipt of Pediatric Disease Designation for Prader-Willi Syndrome
03 Aug 2023 //
PR NEWSWIRE
Aardvark Announces FDA Orphan Drug Designation Granted to ARD-101
20 Jun 2023 //
PR NEWSWIRE
Aardvark Therapeutics announces positive data from ARD-101 trials
13 Jun 2023 //
CLINICAL TRIALS ARENA
Aardvark Therapeutics Reports Positive Phase II Clinical Data for ARD-101
12 Jun 2023 //
PR NEWSWIRE
Aardvark Tx Initiates Enrollment For 3 Phase 2 Clinical Trials Of Oral Ard-101
02 Feb 2022 //
PRNEWSWIRE
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.